MET and neoplasm: An ongoing trial is testing cabozantinib, an inhibitor targeting multiple RTKs (MET and VEGFR2), in combination with ICB in mCRPC (NCT05502315), building on evidence that MET inhibition may enhance anti-tumor immune responses (Jabbarzadeh Kaboli, Roozitalab et al, 2024).